- - 42. The method according to Claim 22, wherein the polysaccharide is xanthan gum.

43. The method according to Claim 22, wherein the polysaccharide is HPMC.

44. The method according to Claim 22, wherein the polysaccharide is present as the sole therapeutically active ingredient.

45. The method according to Claim 22, wherein said polysaccharide is administered in the form of an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.

46. The method according to Claim 22, wherein said polysaccharide is administered in the form of a rectally administrable pharmaceutical composition which is a liquid enema or foam enema.

47. The method according to Claim 22, wherein said polysaccharide is administered in the form of a composition comprised of a liquid enema containing xanthan gum in a concentration of about 0.4 to about 2 % w/w (based on the composition).

48. The method according to Claim 22, wherein said polysaccharide is administered in the form of a composition comprised of a foam enema containing xanthan gum in a concentration of about 1.4 to about 2.5 % w/w (based on the composition).

C1 cont.

49. The method according to Claim 22, wherein said polysaccharide is administered in the form of a composition comprised of a liquid enema containing HPMC in a concentration of about 1 to about 20 % w/w (based on the composition).

50. The method according to Claim 22, wherein said polysaccharide is administered in the form of a composition comprised of a foam enema containing HPMC in a concentration of about 2.5 to about 25 % w/w (based on the composition).

51. The method according to Claim 22, wherein said polysaccharide is administered in the form of a composition comprised of a rectally administrable composition comprised of xanthan gum in an amount of about 400 to about 2000 mg per unit dose.